Development and validation of a cost-utility model for Type1 diabetes mellitus

被引:8
|
作者
Wolowacz, S. [1 ]
Pearson, I. [1 ]
Shannon, P. [2 ]
Chubb, B. [3 ]
Gundgaard, J. [4 ]
Davies, M. [5 ]
Briggs, A. [6 ]
机构
[1] RTI Hlth Solut, Hlth Econ, Manchester, Lancs, England
[2] RTI Hlth Solut, Patient Reported Outcomes, Manchester, Lancs, England
[3] Novo Nordisk Ltd, European Hlth Econ & Outcomes Res, Gatwick, W Sussex, England
[4] Novo Nordisk AS, Hlth Econ & HTA, Bagsvaerd, Denmark
[5] Univ Leicester, Diabet Res Ctr, Leicester, Leics, England
[6] Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland
关键词
RISK-FACTORS; COMPLICATIONS; DISEASE; NEUROPATHY; EURODIAB; COHORT; ONSET;
D O I
10.1111/dme.12663
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AimsTo develop a health economic model to evaluate the cost-effectiveness of new interventions for Type1 diabetes mellitus by their effects on long-term complications (measured through mean HbA(1c)) while capturing the impact of treatment on hypoglycaemic events. MethodsThrough a systematic review, we identified complications associated with Type1 diabetes mellitus and data describing the long-term incidence of these complications. An individual patient simulation model was developed and included the following complications: cardiovascular disease, peripheral neuropathy, microalbuminuria, end-stage renal disease, proliferative retinopathy, ketoacidosis, cataract, hypoglycemia and adverse birth outcomes. Risk equations were developed from published cumulative incidence data and hazard ratios for the effect of HbA(1c), age and duration of diabetes. We validated the model by comparing model predictions with observed outcomes from studies used to build the model (internal validation) and from other published data (external validation). We performed illustrative analyses for typical patient cohorts and a hypothetical intervention. ResultsModel predictions were within 2% of expected values in the internal validation and within 8% of observed values in the external validation (percentages represent absolute differences in the cumulative incidence). ConclusionsThe model utilized high-quality, recent data specific to people with Type1 diabetes mellitus. In the model validation, results deviated less than 8% from expected values. What's new? A simple cost-utility model was developed to evaluate new interventions for Type1 diabetes mellitus by assessing the association between the interventions' effects on mean HbA(1c) and long-term complications and the risk of hypoglycaemic events. High-quality, recently reported data specific to people with Type1 diabetes mellitus were identified by a systematic review. Model validation included review by clinical and economic experts, verification of input data and formulae, and comparison of model predictions with observations from studies used to build the model and other published data.
引用
收藏
页码:1023 / 1035
页数:13
相关论文
共 50 条
  • [21] Development and validation of a risk nomogram model for predicting peripheral neuropathy in patients with type 2 diabetes mellitus
    Luo, Lingguang
    Long, Xinping
    Cheng, Cheng
    Xu, Qian
    Li, Jing
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [22] Impact of Nutraceuticals on Type 1 and Type 2 Diabetes Mellitus-Induced Micro- and Macrovasculopathies
    Mabena, Philanathi
    Fasemore, Thandi M. D.
    Nkomozepi, Pilani
    Alves, Marco G.
    APPLIED SCIENCES-BASEL, 2024, 14 (01):
  • [23] Prenatal Screening for CMV Primary Infection: A Cost-Utility Model
    El Hachem, Gebrael
    Poder, Thomas G.
    Carey, Catherine Mc
    Gantt, Soren
    Kakkar, Fatima
    Sab, Marc
    Renaud, Christian
    Boucoiran, Isabelle
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2025, 132 (06) : 805 - 815
  • [24] Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes
    Palmer, Andrew J.
    Dinneen, Sean
    Gavin, James R., III
    Gray, Alastair
    Herman, William H.
    Karter, Andrew J.
    CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (05) : 861 - 872
  • [25] COST-UTILITY ANALYSIS OF LIRAGLUTIDE VERSUS GLIMEPIRIDE AS ADD-ON TO METFORMIN IN TYPE 2 DIABETES PATIENTS IN CHINA
    Gao, Lan
    Zhao, Fei-Li
    Li, Shu-Chuen
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2012, 28 (04) : 436 - 444
  • [26] Cost-utility of albiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US
    Bruhn, David
    Martin, Alan A.
    Tavares, Ruben
    Hunt, Barnaby
    Pollock, Richard F.
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (07) : 672 - 683
  • [27] Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster)
    McEwan, P
    Peters, JR
    Bergenheim, K
    Currie, CJ
    CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (01) : 121 - 129
  • [28] Socioeconomic deprivation and development of diabetic retinopathy in patients with type 1 diabetes mellitus
    Alvarez-Ramos, Pablo
    Jimenez-Carmona, Soledad
    Alemany-Marquez, Pedro
    Antonio Cordoba-Dona, Juan
    Aguilar-Diosdado, Manuel
    BMJ OPEN DIABETES RESEARCH & CARE, 2020, 8 (02)
  • [29] Lixisenatide for Type 2 Diabetes Mellitus Patients Inadequately Controlled on Oral Antidiabetic Drugs: A Mixed-Treatment Comparison Meta-analysis and Cost-Utility Analysis
    Men, Peng
    Qu, Shuli
    Song, Zhenqiang
    Liu, Yanjun
    Li, Chaoyun
    Zhai, Suodi
    DIABETES THERAPY, 2020, 11 (08) : 1745 - 1755
  • [30] Type 1 Diabetes Mellitus and Thromboembolism in Pregnancy
    Thomas, Jacob
    Brewerton, Charles
    Holmgren, Calla
    Harrison, Rachel
    AMERICAN JOURNAL OF PERINATOLOGY, 2025,